Physician profile
Jeffrey Mark Henderson
NPI 1912988007
$1,180.94
in general payments reported to CMS, 2019-2025
15 companies · $36.24 in 2025
The $36.24 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $66.30 · 2021: $279 · 2022: $365 · 2023: $96.22 · 2024: $122 · 2025: $36.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $296.77 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $157.88 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $155.58 | 2021-2024 | Qelbree |
| Merck Sharp & Dohme LLC | $122.98 | 2021-2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Shire North American Group INC | $71.41 | 2019 | |
| Ironshore Pharmaceuticals INC. | $54.40 | 2019 | |
| Genentech USA, INC. | $47.40 | 2019-2021 | |
| Tris Pharma INC | $45.56 | 2019-2022 | |
| Cranial Technologies, INC | $44.17 | 2021-2023 | Doc Band |
| Zimmer Biomet Holdings, INC. | $41.72 | 2019 | |
| Pfizer INC. | $40.19 | 2023-2024 | |
| Sanofi Pasteur INC. | $38.55 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.18 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.84 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.31 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.